What if you could increase the operational efficiency of your studies while reducing the volume of wasted product, allowing for faster completion times and more reliable study results?
Gavin Morgan
Gavin shares how using Speed to PatientTM supported cross-border drug supply during the COVID-19 pandemic.
Crystal Smith
Crystal talks about PCI's Speed to Patient offering and how it helped with a global orphan drug study.
FACTS
The recruitment and retention of qualified patients can be challenging
94% of potential patients don’t have access to clinical trials due to location/travel complexities
50% of clinical trial visits could be relocated to a patients home
FEATURES
The PCI WayTM - implementing Direct to Patient protocols: delivering life-changing therapies to those who need it most, anywhere in the world
“Accelerate your clinical trial distribution by leveraging PCI’s Speed to PatientTM solution.”
Kim Johnson-Cavanaugh
Director, Clinical Project Management
"Because patients are assured of potential time and cost-savings as well as additional conveniences when participating in Direct-to-Patient clinical trials versus traditional studies, use of the model has increased patient recruitment by up to 60 percent and helped maintain patient retention at over 95 percent."
BENEFITS
